Citius Pharmaceuticals, Inc.: other noncurrent assets

What this measure means

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Exact concept: us-gaap:OtherAssetsNoncurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2023-09-30 to 2025-09-30. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• Citius Pharmaceuticals, Inc.: total assets
• Citius Pharmaceuticals, Inc.: total liabilities
• Citius Pharmaceuticals, Inc.: stockholders equity
• Citius Pharmaceuticals, Inc.: cash and cash equivalents
• Citius Pharmaceuticals, Inc.: net income or loss
• Citius Pharmaceuticals, Inc.: operating cash flow
• Citius Pharmaceuticals, Inc.: capital expenditure payments
• Citius Pharmaceuticals, Inc.: revenue
• Citius Pharmaceuticals, Inc.: financing cash flow
• Citius Pharmaceuticals, Inc.: investing cash flow
• Citius Pharmaceuticals, Inc.: retained earnings or deficit
• Citius Pharmaceuticals, Inc.: basic weighted-average shares
• Citius Pharmaceuticals, Inc.: diluted weighted-average shares
• Citius Pharmaceuticals, Inc.: basic earnings per share
• Citius Pharmaceuticals, Inc.: diluted earnings per share
• Citius Pharmaceuticals, Inc.: income tax expense or benefit
• Citius Pharmaceuticals, Inc.: net property, plant and equipment
• Citius Pharmaceuticals, Inc.: share-based compensation expense
• Citius Pharmaceuticals, Inc.: operating income or loss
• Citius Pharmaceuticals, Inc.: current assets
• Citius Pharmaceuticals, Inc.: interest expense
• Citius Pharmaceuticals, Inc.: current liabilities
• Citius Pharmaceuticals, Inc.: current accounts payable
• Citius Pharmaceuticals, Inc.: goodwill carrying amount
• Citius Pharmaceuticals, Inc.: operating expenses
• Citius Pharmaceuticals, Inc.: research and development expense
• Citius Pharmaceuticals, Inc.: common shares outstanding
• Citius Pharmaceuticals, Inc.: cash including restricted cash
• Citius Pharmaceuticals, Inc.: additional paid-in capital
• Citius Pharmaceuticals, Inc.: total equity including noncontrolling interests
• Citius Pharmaceuticals, Inc.: operating lease right-of-use asset
• Citius Pharmaceuticals, Inc.: operating lease liability
• Citius Pharmaceuticals, Inc.: accrued current liabilities
• Citius Pharmaceuticals, Inc.: net deferred tax liabilities
• Citius Pharmaceuticals, Inc.: pre-tax income or loss from continuing operations
• Citius Pharmaceuticals, Inc.: profit or loss including noncontrolling interests
• Citius Pharmaceuticals, Inc.: net income available to common stockholders
• Citius Pharmaceuticals, Inc.: general and administrative expense
• Citius Pharmaceuticals, Inc.: depreciation expense
• Citius Pharmaceuticals, Inc.: nonoperating income or expense
• Citius Pharmaceuticals, Inc.: deferred income tax expense or benefit
• Citius Pharmaceuticals, Inc.: interest paid, net
• Citius Pharmaceuticals, Inc.: proceeds from issuing common stock
• Citius Pharmaceuticals, Inc.: change in accounts payable

Inspect the source

Entity

Citius Pharmaceuticals, Inc. / CIK 0001506251

Captured

2026-09-20T09:12:24.553Z

SEC response SHA-256

dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))